Y Intercept Hong Kong Ltd Lowers Holdings in Xeris Biopharma Holdings, Inc. $XERS

Y Intercept Hong Kong Ltd decreased its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 75.6% in the third quarter, HoldingsChannel.com reports. The fund owned 82,181 shares of the company’s stock after selling 254,033 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Xeris Biopharma were worth $669,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in XERS. Qube Research & Technologies Ltd lifted its holdings in Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after purchasing an additional 1,245,188 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares in the last quarter. CenterBook Partners LP boosted its position in shares of Xeris Biopharma by 237.7% during the second quarter. CenterBook Partners LP now owns 1,594,229 shares of the company’s stock worth $7,445,000 after acquiring an additional 1,122,154 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Xeris Biopharma by 108.3% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,227,959 shares of the company’s stock worth $5,735,000 after acquiring an additional 638,488 shares during the last quarter. Finally, Norges Bank purchased a new position in Xeris Biopharma during the second quarter valued at $2,623,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

XERS has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a report on Friday, January 9th. Zacks Research downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Finally, Oppenheimer reiterated an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a research report on Friday, November 7th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Xeris Biopharma has an average rating of “Moderate Buy” and an average target price of $10.08.

Xeris Biopharma Stock Performance

XERS opened at $7.36 on Tuesday. The stock has a 50-day moving average of $7.28 and a 200 day moving average of $7.49. Xeris Biopharma Holdings, Inc. has a 12 month low of $3.44 and a 12 month high of $10.08. The firm has a market cap of $1.22 billion, a P/E ratio of -73.59 and a beta of 0.52.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.01 by ($0.01). The business had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. On average, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Activity

In other Xeris Biopharma news, insider Kevin Mcculloch sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $8.00, for a total transaction of $120,000.00. Following the completion of the transaction, the insider owned 1,685,426 shares in the company, valued at $13,483,408. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director John Johnson sold 135,400 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $7.22, for a total value of $977,588.00. Following the transaction, the director directly owned 698,083 shares in the company, valued at approximately $5,040,159.26. This represents a 16.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 280,217 shares of company stock worth $2,041,841 in the last 90 days. Company insiders own 4.56% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.